Table 1 Multivariate analysis of the factors associated with prices^d of pediatric antiretrovirals

2005

−0.06

[−0.14, 0.02]

0.00

[−0.10, 0.09]

−0.13

[−0.27, 0.00]

2006

−0.21^c

[−0.29, −0.13]

−0.14^b

[−0.24, −0.04]

−0.30^c

[−0.44, −0.17]

2007

−0.33^c

[−0.40, −0.26]

−0.1^c

[−0.28, −0.10]

−0.46^c

[−0.58, −0.34]

2008

−0.45^c

[−0.52, −0.38]

−0.27^c

[−0.36, −0.19]

−0.56^c

[−0.68, −0.44]

2009

−0.49^c

[−0.56, −0.41]

−0.33^c

[−0.43, −0.23]

−0.60^c

[−0.73, −0.47]

2010

−0.50^c

[−0.57, −0.43]

−0.29^c

[−0.38, −0.19]

−0.62^c

[−0.75, −0.50]

2011

−0.45^c

[−0.53, −0.38]

−0.45^c

[−0.56, −0.35]

−0.50^c

[−0.62, −0.38]

2012

−0.48^c

[−0.56, −0.41]

−0.52^c

[−0.63, −0.41]

−0.54^c

[−0.66, −0.41]

East Asia and Pacific

−0.03

[−0.07, 0.02]

0.26^c

[0.17, 0.35]

−0.11^c

[−0.16, −0.06]

Europe and Central Asia

0.28^c

[0.22, 0.33]

0.66^c

[0.56, 0.76]

0.08^a

[0.02, 0.14]

Latin America and the Caribbean

0.07^b

[0.02, 0.11]

0.31^c

[0.23, 0.38]

0.00

[−0.05, 0.05]

Middle East and North Africa

0.08

[0.00, 0.17]

0.29^c

[0.14, 0.44]

−0.05

[−0.14, 0.05]

South Asia

−0.13^c

[−0.20, −0.06]

0.13

[−0.18, 0.44]

−0.13^c

[−0.21, −0.06]

South Africa

−0.23^c

[−0.29, −0.18]

−0.71^c

[−0.81, −0.61]

0.24^c

[0.17, 0.31]

Lower-middle income countries

0.04^b

[0.02, 0.07]

0.14^c

[0.09, 0.20]

0.02

[−0.01, 0.05]

Upper-middle income countries

0.17^c

[0.12, 0.22]

0.48^c

[0.39, 0.58]

0.02

[−0.04, 0.07]

Double

0.01

[−0.04, 0.05]

0.10^c

[0.05, 0.16]

−0.35^c

[−0.42, −0.29]

Triple

−0.08^b

[−0.15, −0.02]

−0.48^c

[−0.56, −0.40]

1 additional manufacturer

−0.04^c

[−0.04, −0.03]

−0.02^c

[−0.03, −0.01]

−0.08^c

[−0.09, −0.07]

Log(quantity purchased)

−0.10^c

[−0.10, −0.09]

−0.11^c

[−0.12, −0.10]

−0.10^c

[−0.10, −0.09]

Originator

0.72^c

[0.70, 0.75]

Adjusted R²

Sum of squared residuals